NCT06962774View on ClinicalTrials.gov

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 9, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Renal Impairment
Interventions
DRUG

ESK-001

Single oral dose of ESK-001 in participants from all cohorts

Trial Locations (4)

32809

RECRUITING

Orlando Clinical Research Center, Orlando

33014

RECRUITING

Panax Clinical Research, Miami Lakes

33016

RECRUITING

Floridian Clinical Research, Miami Lakes

33147

RECRUITING

Advanced Pharma CR, Miami

Sponsors

Lead Sponsor

Alumis Inc
All Listed Sponsors
lead

Alumis Inc

INDUSTRY

NCT06962774 - An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function | Biotech Hunter | Biotech Hunter